Defining factors that influence vaccine-induced, cross-variant neutralizing antibodies for SARS-CoV-2 in Asians
Gu, Y.; Shunmuganathan, B. D.; Qian, X.; Gupta, R.; Tan, R. S. W.; Kozma, M.; Purushotorman, K.; Murali, T. M.; Tan, N. Y. J.; Preiser, P. R.; Lescar, J.; Nasir, H.; Somani, J.; Tambyah, P. A.; SCOPE Cohort Study Group, ; Smith, K. G. C.; Renia, L.; Ng, L. F. P.; Lye, D. C.; Young, B. E.; MacAry, P. A.
Show abstract
The scale and duration of neutralizing antibody responses targeting SARS-CoV-2 viral variants represents a critically important serological parameter that predicts protective immunity for COVID-19. In this study, we present longitudinal data illustrating the impact of age, sex and comorbidities on the kinetics and strength of vaccine-induced neutralizing antibody responses for key variants in an Asian volunteer cohort. We demonstrate a reduction in neutralizing antibody titres across all groups six months post-vaccination and show a marked reduction in the serological binding and neutralizing response targeting Omicron compared to other viral variants. We also highlight the increase in cross-protective neutralizing antibody responses against Omicron induced by a third dose (booster) of vaccine. These data illustrate how key virological factors such as immune escape mutation combined with host factors such as age and sex of the vaccinated individuals influence the strength and duration of cross-protective serological immunity for COVID-19.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice 96%
- Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates 95%
- A stabilized MERS-CoV spike ferritin nanoparticle vaccine elicits robust and protective neutralizing antibody responses 95%
Similar papers in this journal
- Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 97%
- Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity 97%
- Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2 97%
Similar papers in this journal
- Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19 96%
- Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals 96%
- Structure and function of a cross-neutralizing influenza neuraminidase antibody that accommodates recent N2 NA Asn245 glycosylation 95%
Similar papers in this journal
- Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination 94%
- Autoantibodies in COVID-19 correlate with anti-viral humoral responses and distinct immune signatures 92%
- Allergic inflammation triggers dyslipidemia via IgG signalling 91%
Similar papers in this journal
- COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection 96%
- Clinical course impacts early kinetics and long-term magnitude and amplitude of SARS-CoV-2 neutralizing antibodies beyond one year after infection 95%
- Protective antibodies and T cell responses to Omicron variant three months after the booster dose of BNT162b2 vaccine 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.